바카라 사이트 Biotech raises KRW 36.6 billion with a 103.95% subscription rate for paid-in capital increase

[by Ji, Yong Jun] 바카라 사이트 Biotech announced on August 19 that it has successfully finalized a paid-in capital increase of KRW 36.6 billion (approximately USD 26.2 million). The company reported a subscription rate of 103.95% among existing shareholders, thereby completing a capital-raising process without the need for a general public offering.

바카라 사이트 Biotech reported that during the subscription period for existing shareholders, held on August 14 and 18, the company achieved a total subscription rate of 103.95%, inclusive of oversubscriptions. Specifically, excluding oversubscriptions, shareholders who were granted warrants received 33,813,404 shares, accounting for 88.9% of the targeted 38 million shares. With the addition of 5,688,248 oversubscribed shares, the final subscription number reached 39,501,652 shares. As a result, 바카라 사이트 Biotech successfully concluded the subscription process without the need for a general public offering of forfeited shares, thereby securing KRW 36.6 billion in capital.

바카라 사이트 Biotech has successfully concluded a Phase 1 clinical trial for its lead pipeline candidate, OSCA, developed as a treatment option for knee osteoarthritis. The company is currently conducting a Phase 2a clinical trial involving 108 patients, with patient dosing scheduled for completion in October. Based on the anticipated release of top-line clinical data in July 2026, 바카라 사이트 Biotech intends to pursue global licensing-out opportunities.